209 related articles for article (PubMed ID: 32395117)
21. Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus.
Gavvovidis I; Leisegang M; Willimsky G; Miller N; Nghiem P; Blankenstein T
Clin Cancer Res; 2018 Aug; 24(15):3644-3655. PubMed ID: 29669806
[No Abstract] [Full Text] [Related]
22. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein.
Meng WS; Butterfield LH; Ribas A; Heller JB; Dissette VB; Glaspy JA; McBride WH; Economou JS
Mol Immunol; 2000 Nov; 37(16):943-50. PubMed ID: 11395133
[TBL] [Abstract][Full Text] [Related]
23. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.
Raman MC; Rizkallah PJ; Simmons R; Donnellan Z; Dukes J; Bossi G; Le Provost GS; Todorov P; Baston E; Hickman E; Mahon T; Hassan N; Vuidepot A; Sami M; Cole DK; Jakobsen BK
Sci Rep; 2016 Jan; 6():18851. PubMed ID: 26758806
[TBL] [Abstract][Full Text] [Related]
24. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
25. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
Kondo K; Fujiki F; Nakajima H; Yatsukawa E; Morimoto S; Tatsumi N; Nishida S; Nakata J; Oka Y; Tsuboi A; Hosen N; Oji Y; Sugiyama H
J Immunother; 2016 Apr; 39(3):127-39. PubMed ID: 26938946
[TBL] [Abstract][Full Text] [Related]
26. Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
Simister PC; Border EC; Vieira JF; Pumphrey NJ
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851311
[TBL] [Abstract][Full Text] [Related]
27. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
[TBL] [Abstract][Full Text] [Related]
28. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
[TBL] [Abstract][Full Text] [Related]
29. Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer.
Audehm S; Glaser M; Pecoraro M; Bräunlein E; Mall S; Klar R; Effenberger M; Albers J; Bianchi HO; Peper J; Yusufi N; Busch DH; Stevanović S; Mann M; Antes I; Krackhardt AM
Front Immunol; 2019; 10():1485. PubMed ID: 31316521
[TBL] [Abstract][Full Text] [Related]
30. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
[TBL] [Abstract][Full Text] [Related]
31. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.
Ohta K; Yamaguchi Y; Shimizu K; Miyahara E; Toge T
Anticancer Res; 2002; 22(5):2597-606. PubMed ID: 12529970
[TBL] [Abstract][Full Text] [Related]
32. TCR3: a third T-cell receptor in the chicken.
Chen CH; Sowder JT; Lahti JM; Cihak J; Lösch U; Cooper MD
Proc Natl Acad Sci U S A; 1989 Apr; 86(7):2351-5. PubMed ID: 2648400
[TBL] [Abstract][Full Text] [Related]
33. Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma.
Nakagawa H; Mizukoshi E; Kobayashi E; Tamai T; Hamana H; Ozawa T; Kishi H; Kitahara M; Yamashita T; Arai K; Terashima T; Iida N; Fushimi K; Muraguchi A; Kaneko S
Gastroenterology; 2017 May; 152(6):1395-1406.e10. PubMed ID: 28188748
[TBL] [Abstract][Full Text] [Related]
34. A Potent Tumor-Reactive p53-Specific Single-Chain TCR without On- or Off-Target Autoimmunity In Vivo.
Echchannaoui H; Petschenka J; Ferreira EA; Hauptrock B; Lotz-Jenne C; Voss RH; Theobald M
Mol Ther; 2019 Jan; 27(1):261-271. PubMed ID: 30528087
[TBL] [Abstract][Full Text] [Related]
35. CrossDome: an interactive R package to predict cross-reactivity risk using immunopeptidomics databases.
Fonseca AF; Antunes DA
Front Immunol; 2023; 14():1142573. PubMed ID: 37377956
[TBL] [Abstract][Full Text] [Related]
36. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
37. TCRs with Distinct Specificity Profiles Use Different Binding Modes to Engage an Identical Peptide-HLA Complex.
Coles CH; Mulvaney RM; Malla S; Walker A; Smith KJ; Lloyd A; Lowe KL; McCully ML; Martinez Hague R; Aleksic M; Harper J; Paston SJ; Donnellan Z; Chester F; Wiederhold K; Robinson RA; Knox A; Stacey AR; Dukes J; Baston E; Griffin S; Jakobsen BK; Vuidepot A; Harper S
J Immunol; 2020 Apr; 204(7):1943-1953. PubMed ID: 32102902
[TBL] [Abstract][Full Text] [Related]
38. Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody.
Bernardeau K; Gouard S; David G; Ruellan AL; Devys A; Barbet J; Bonneville M; Chérel M; Davodeau F
Eur J Immunol; 2005 Oct; 35(10):2864-75. PubMed ID: 16163672
[TBL] [Abstract][Full Text] [Related]
39. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
[TBL] [Abstract][Full Text] [Related]
40. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L; Hombrink P; Hagedoorn RS; Kester MG; van der Steen DM; Rodriguez T; Pentcheva-Hoang T; de Ru AH; Schoonakker MP; Meeuwsen MH; Griffioen M; van Veelen PA; Falkenburg JH; Heemskerk MH
Blood; 2017 Mar; 129(10):1284-1295. PubMed ID: 28053195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
